NSAIDs (non-steroidal anti-inflammatory drugs) Flashcards
NSAIDs
- weak acids
- work on modulation and transduction
- main effects: prevent inflammation by inhibiting COX (cyclooxygenase) enzymes, most commonly used analgesics, potential adverse effects
- other uses: anti-pyretic, inhibit tumor growth
mechanism of action of NSAIDs
- glucocorticoids work on phospholipases
- NSAIDs work on COX 1 and 2, cause prostaglandins to cause vasodilation, fever, pain
- piprants work on prostaglandins
- Dual Cox/ 5-LOX inhibitors work on 5-lipoxygenase
- leukotriene inhibitors work on leukotrienes
- do not use NSAIDs and steroids together
COX-1
- production of prostaglandins, play important role in normal homeostasis
- thromboxane A2- COX mediated, promotes platelet aggregation in normal homeostasis
- prostaglandin E1- involved with GI mucosal maintenance and vasodilation in kidney in response to decreased blood flow- GI signs and gastric ulcers are important adverse effect (especially if NSAID and steroid are combined)
COX-2
- inducible production of prostaglandins- produced during inflammation
- selectivity of COX-2 by NSAID is important when considering side effects, toxic effects, and dose
selective COX-2 inhibition
- RX only
- carprofen, deracoxib, robencoxib, pirocoxib, meloxicam, piroxicam
non-selective COX-1 and 2 inhibition
-phenylbutazone, Flunixin meglumine
selective COX-1 inhibition
-aspirin (strongest acid NSAID)
glucocorticoids
-prednisone/prednisolone
lipoxygenase inhibitors
-montelukast (singulair)
Anti-inflammatory effects of NSAIDs
- inhibit synthesis of eiconsanoids (thromboxane, prostacyclin, prostaglandins)
- not as potent anti-inflammatory agents as glucocorticoids
- do not delay wound healing or lead to immunosupression
- greater effect on acute inflammation
analgesic effects of NSAIDs
- provide analgesia whether inflammation is present or not
- decrease prostaglandin sensitization of neurons
- centrally, interaction of prostaglandins with nociception
antipyretic effects of NSAIDs
- decrease fever, will not reduce hyperthermia of normal body temp, endotoxins produce interleukins that cause fever
- underlying cause for fever should be diagnosed and addressed
antiendotoxic effects of NSAIDs
beneficial if given before endotoxic challenge
Pharmacokinestics of NSAIDs
- highly protein bound (95-99%)
- generally good absorption PO or IM - some may adsorb to feed and cause decreased GI absorption
- low Vd- inflammation or increase in vascular permeability leads to extravasation of plasma proteins carrying drugs with it, displacement may occur if used concurrently with other highly bound protein drugs
- can cross BBB into CNS
- some may distribute into milk
- note drug specific differences
metabolism and excretion of NSAIDs
- hepatic metabolism (phase 1 and II in liver)
- differences between species, breeds, individuals
- ex: dogs with CYP2D15 enzyme metabolize 3x faster
- some NSAIDs are converted to active metabolites
- ASA–> salicyclic acid
- phenylbutazone–>oxyphenobutazone
- metabolites eliminated in urine- small amount unchanged via tubular secretion
- bilary excretion and enterohepatic recirculation in some NSAIDs- naproxen very toxic to dogs
- drug excretion almost complete after 5 half lives
special use of NSAIDs
- antithrombotic effects- inhibit TXA2- low dose aspirin/ASA, TXA2 is platelet aggregating factor, causes PGI2 (platelet aggregating agent)= less inhibited, increased clotting time
- antineoplastic effects- COX-2 expressed in some cancer, transitional cell carcinoma and osteosarcoma, Piroxicam used for this
adverse effects NSAIDs
- GI irritation/ulceration- due to inhibition of prostaglandins
- all NSAIDs can cause vomiting, diarrhea, anorexia, with steroids increased chance of ulcers
- renal damage, decreased blood flow- PGs control vasodilation of renal vascular beds, risk increases with overdose or other risk factors present, risk increases in cats
- don’t use NSAIDs post op until anesthesia is cleared
- hepatotoxicity- acetiminophen can produce toxic intermediates by phase 1 metabolism, greater production in cats, may occur idiosyncratically/dose dependent
- less common adverse effects- bleeding, bone marrow suppresion/agranulocytis
Flunixin Meglumine (Banamine)
- large animal NSAID- don’t use in small animals
- main clinical use- analgesic for colic and endotoxemia in horses, visceral pain in cattle, also for acute pulmonary emphysema
- route of administration- PO- horses, IV cattle, IM swine, rarely seen anyphylaxis after IV administration
- do not use IM in horses- muscle necrosis
- intracorotid can cause seizures/CNS stimulation
- caution with GI, renal, hepatic, hematological dz
- avoid in birds, renal toxicity
Phenylbutazone (Bute)
- common in horses, banned in dairy cattle
- main clincal uses: musculoskeletal pain
- route of administration- PO, IV, can cause sloughing and necrosis in IM/SC
- intracorotid injection= seizures/CNS
- can mask lameness- withdrawal time for racing animals
COX-2 preferentials
-Carprofen
-Meloxicam
Deracoxib
-small animal med- analgesics and antiinflammatory
-oral: tablets, liquids, transmucosal for meloxicam
-carprofen and meloxicam- injectable SQ
-meloxicam is single injection in cats
COX-2 selectives
- Firocoxib- oral paste in horses, chewable tablets in dogs
- Robenacoxib- first NSAID approved for multiple doses in cats, appears effective with similar safety profile in dogs when compared to Meloxicam for post-op anesthesia
Washout periods
- NSAID–> sterood 1-2 wks
- Steroid–> NSAID- wean steriod, minimum 1 wk washout
- 2 different NSAIDs washout based on half life ~1 wk
Acetaminophen “non-NSAID”
- non-anti-inflammatory, antipyretic analgesic
- no significant anti-platelet effect
- MOA and metabolism: does not inhibit COX, interferes with conversion of endoperoxidases to other PGs and TXs, may be more effective with PG synthesis inhibition in CNS, hepatic metabolism
- clinical use: dogs only
- toxicity: methemoglobinemia, hepatic necrosis, cats extremely sensitive, hemolysis, icterus, anemia, Heinz bodies, facial swelling, edema
other analgesics- Gapiprant
- piprant
- non-COX inhibiting, non-NSAID
- MOA: antagonist at PGE2 E4 receptor which subdues pain and inflammation, some GI and renal effects
Gabapentin
- neural steroid- dogs, cats, horses
- anti-hyperalgesic- wide therapeutic margin, minimal side effects
- main clinical uses: control of neuropathic pain–> can prevent allodynia, laminitis, pre-emptively for acute pain, augments analgesic effect of other drugs, adjunct therapy for refractory complex seizures
- MOA- not well known, alter Ca+ influx in neuronal cells
- precautions: may cause sedation/ataxia- dose dependent effects, renal excretion, beware renal insufficiency
Amantadine
- antiviral drug with NMDA receptor agonist properties- narrow therapeutic window in small animals
- MOA of analgesic effects: NMDA receptor agonist, dorsal horn of spinal cord “wind up pain”
- main clinical uses: less common adjunctive analgesic in small animals- chronic pain , neuropathic pain “dorsal horn wind up”, oral
omega-3 FA
- produced by COX, LOX, cytochrome P450 pathways
- help reduce and clear up inflammation